Clinical Trial: NCT04467021
Cancer and Blood Pressure Management, CARISMA Study
Status:
ACTIVE NOT RECRUITINGPhase:
Not Applicable| Lead Sponsor: | ECOG-ACRIN Cancer Research Group |
| Information Provided By: | Eastern Cooperative Oncology Group |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.
Official Title
Conditions
Intervention / Treatment
- Other: Best Practice
- Other: Blood Pressure Measurement
- Other: Clinical Management
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
Other Study ID Numbers
- EAQ191
- NCI-2020-00900
- EAQ191
- ECOG-ACRIN-EAQ191
- EAQ191
- UG1CA189828
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | ECOG-ACRIN Cancer Research Group |
| Information Provided By: | Eastern Cooperative Oncology Group |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.
Official Title
Conditions
Intervention / Treatment
- Other: Best Practice
- Other: Blood Pressure Measurement
- Other: Clinical Management
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
Other Study ID Numbers
- EAQ191
- NCI-2020-00900
- EAQ191
- ECOG-ACRIN-EAQ191
- EAQ191
- UG1CA189828